These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16458605)

  • 1. HIV-specific CD4+ T cells and viremia: who's in control?
    Jansen CA; van Baarle D; Miedema F
    Trends Immunol; 2006 Mar; 27(3):119-24. PubMed ID: 16458605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation.
    McNeil AC; Shupert WL; Iyasere CA; Hallahan CW; Mican JA; Davey RT; Connors M
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13878-83. PubMed ID: 11717444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
    Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M
    J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity.
    Younes SA; Yassine-Diab B; Dumont AR; Boulassel MR; Grossman Z; Routy JP; Sekaly RP
    J Exp Med; 2003 Dec; 198(12):1909-22. PubMed ID: 14676302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of preserving HIV-specific immune responses.
    Kaufmann DE; Rosenberg ES
    J HIV Ther; 2003 Feb; 8(1):19-25. PubMed ID: 12840711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART.
    Jones LE; Perelson AS
    Bull Math Biol; 2005 Nov; 67(6):1227-51. PubMed ID: 16023709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients.
    Keh CE; Shen JM; Hahn B; Hallahan CW; Rehm CA; Thaker V; Wynne SM; Davey RT; Lane HC; Sereti I
    AIDS; 2006 Feb; 20(3):361-9. PubMed ID: 16439869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure.
    Correa R; Harari A; Vallelian F; Resino S; Munoz-Fernandez MA; Pantaleo G
    AIDS; 2007 Jan; 21(1):23-30. PubMed ID: 17148964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity.
    Jansen CA; Piriou E; De Cuyper IM; van Dort K; Lange JM; Miedema F; van Baarle D
    Antivir Ther; 2006; 11(1):105-16. PubMed ID: 16518966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy.
    Siddique MA; Hartman KE; Dragileva E; Dondero M; Gebretsadik T; Shintani A; Peiperl L; Valentine F; Kalams SA
    J Infect Dis; 2006 Sep; 194(5):661-5. PubMed ID: 16897665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus.
    Altfeld M; Allen TM; Yu XG; Johnston MN; Agrawal D; Korber BT; Montefiori DC; O'Connor DH; Davis BT; Lee PK; Maier EL; Harlow J; Goulder PJ; Brander C; Rosenberg ES; Walker BD
    Nature; 2002 Nov; 420(6914):434-9. PubMed ID: 12459786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals.
    Lévy Y; Durier C; Lascaux AS; Meiffrédy V; Gahéry-Ségard H; Goujard C; Rouzioux C; Resch M; Guillet JG; Kazatchkine M; Delfraissy JF; Aboulker JP;
    AIDS; 2006 Feb; 20(3):405-13. PubMed ID: 16439874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTL escape and increased viremia irrespective of HIV-specific CD4+ T-helper responses in two HIV-infected individuals.
    Geels MJ; Jansen CA; Baan E; De Cuyper IM; van Schijndel GJ; Schuitemaker H; Goudsmit J; Pollakis G; Miedema F; Paxton WA; van Baarle D
    Virology; 2006 Feb; 345(1):209-19. PubMed ID: 16246391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of HIV-1-specific CD8 T-cell responses and their role in loss of viremia in children chronically infected with HIV-1 undergoing highly active antiretroviral therapy.
    Zhang Z; Zhao QX; Fu JL; Yao JX; He Y; Jin L; Wang FS
    Chin Med J (Engl); 2006 Dec; 119(23):1949-57. PubMed ID: 17199938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of in vivo and ex vivo levels of TH1 and TH2 cytokines with viremia in HAART patients with and without opportunistic infections.
    Sindhu S; Toma E; Cordeiro P; Ahmad R; Morisset R; Menezes J
    J Med Virol; 2006 Apr; 78(4):431-9. PubMed ID: 16482539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shift of CMV-specific CD4+ T-cells to the highly differentiated CD45RO-CD27- phenotype parallels loss of proliferative capacity and precedes progression to HIV-related CMV end-organ disease.
    Bronke C; Jansen CA; Westerlaken GH; De Cuyper IM; Miedema F; Tesselaar K; van Baarle D
    Clin Immunol; 2007 Aug; 124(2):190-9. PubMed ID: 17556025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major CD4 epitopes involved in anti-CD4 T-cell autoimmunity in HIV-1 patients.
    Abulafia-Lapid R; Keren-Zur Y; Yachnin Y; Atlan H
    Vaccine; 2007 Apr; 25(16):3192-9. PubMed ID: 17298856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1.
    Deeks SG; Martin JN; Sinclair E; Harris J; Neilands TB; Maecker HT; Hagos E; Wrin T; Petropoulos CJ; Bredt B; McCune JM
    J Infect Dis; 2004 Jan; 189(2):312-21. PubMed ID: 14722897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.